Brokerages Set Liquidia Co. (NASDAQ:LQDA) Target Price at $25.38

Liquidia Co. (NASDAQ:LQDA) has received an average rating of “Buy” from the nine analysts that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold rating, six have given a buy rating and two have given a strong buy rating to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $25.38.

Several brokerages have weighed in on LQDA. HC Wainwright reaffirmed a “buy” rating and issued a $29.00 target price on shares of Liquidia in a research report on Thursday, November 14th. Scotiabank initiated coverage on shares of Liquidia in a research note on Wednesday, October 16th. They issued a “sector outperform” rating and a $30.00 target price for the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $19.00 price objective on shares of Liquidia in a research note on Thursday, January 9th. Lifesci Capital began coverage on shares of Liquidia in a research report on Thursday, October 3rd. They set an “outperform” rating and a $30.00 target price on the stock. Finally, Wells Fargo & Company began coverage on Liquidia in a research report on Friday, December 20th. They issued an “overweight” rating and a $20.00 price target for the company.

Insider Buying and Selling at Liquidia

In other Liquidia news, insider Rajeev Saggar sold 2,526 shares of the company’s stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $11.19, for a total value of $28,265.94. Following the completion of the transaction, the insider now owns 204,857 shares of the company’s stock, valued at $2,292,349.83. This represents a 1.22 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders have sold 5,226 shares of company stock valued at $59,343 in the last 90 days. 30.10% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of LQDA. BNP Paribas Financial Markets boosted its position in shares of Liquidia by 735.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 140,190 shares of the company’s stock valued at $1,402,000 after acquiring an additional 123,402 shares in the last quarter. Whitefort Capital Management LP raised its holdings in shares of Liquidia by 119.8% in the 3rd quarter. Whitefort Capital Management LP now owns 1,702,025 shares of the company’s stock worth $17,020,000 after buying an additional 927,546 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Liquidia by 144.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 390,257 shares of the company’s stock valued at $3,903,000 after buying an additional 230,820 shares in the last quarter. Barclays PLC grew its position in Liquidia by 265.0% in the third quarter. Barclays PLC now owns 99,984 shares of the company’s stock valued at $999,000 after acquiring an additional 72,591 shares during the period. Finally, Sapient Capital LLC bought a new position in shares of Liquidia during the third quarter valued at $1,336,000. 64.54% of the stock is currently owned by institutional investors and hedge funds.

Liquidia Stock Down 3.5 %

LQDA stock opened at $11.76 on Friday. The company has a 50 day moving average of $11.18 and a two-hundred day moving average of $11.02. Liquidia has a 12-month low of $8.26 and a 12-month high of $16.99. The company has a market cap of $995.33 million, a price-to-earnings ratio of -7.21 and a beta of 0.23.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).